European Approval Fuels Investor Optimism for ImmunityBio

ImmunityBio gains EU approval for ANKTIVA, driving stock volatility and 700% revenue growth, but financial risks remain for investors.

ImmunityBio shares experienced significant volatility this week following a major regulatory milestone in Europe. The biotech firm announced that the European Commission has granted conditional marketing authorization for its drug, ANKTIVA. This decision triggered a sharp increase in trading volume and propelled the stock to notable gains. The central question for investors is whether this marks the beginning of a sustained revaluation for the company or if underlying financial risks remain a primary concern.

Operational Momentum and Financial Performance

Beyond the regulatory news, ImmunityBio is demonstrating substantial operational growth. The company reported preliminary net product revenue of $113 million for January 2026. This figure represents a staggering year-over-year increase of 700%. This growth trajectory is further supported by the recent assignment of a permanent J-Code in the United States, which streamlines insurance reimbursement processes for the therapy.

The market reaction to the European authorization was pronounced. At its peak, the stock price climbed to $8.68. Trading activity surged, with approximately 79.2 million shares changing hands—an 87% increase over the average volume. The company's market capitalization temporarily reached around $8.41 billion.

Details of the European Authorization

The conditional approval from Brussels covers ANKTIVA in combination with BCG therapy for adult patients with a specific form of bladder cancer (NMIBC CIS) who have not responded to prior treatments. The authorization is valid across 33 European countries.

For patients, this decision represents a critical new option. It is the first immunotherapy available in Europe for this high-risk group, where the only remaining alternative has often been a radical cystectomy—the surgical removal of the bladder. The Commission's ruling was based on Phase 2 and 3 clinical trial data, which demonstrated durable complete remissions with a favorable safety profile.

Expansion Plans and Persistent Challenges

Capitalizing on this momentum, ImmunityBio is accelerating its global expansion strategy. Less than two years after receiving U.S. FDA approval, the company is now establishing a European presence. This effort is being facilitated through a new office in Ireland and the formation of strategic distribution partnerships. Progress is also being made in the Middle East through collaborative work with Saudi Arabian regulatory authorities.

Despite these positive developments, analysts point to several risk factors. The company's balance sheet presents challenges, including negative shareholder equity and future financing requirements. Market observers have also noted investigations initiated by a law firm on behalf of investors, alongside insider selling activity that occurred in January.

Investor attention is now firmly fixed on upcoming catalysts. ImmunityBio is scheduled to present at the ASCO conference in late February. This will be followed by the official release of its quarterly financial results on March 2, 2026. These events are expected to provide crucial insight into the company's ability to translate its regulatory achievements into long-term financial stability.